Announcements Trials
Browse Landscape

Phase

Phase 1 6Phase 2 1

Status

Completed 5Unknown 1

Sponsor Class

INDUSTRY 6OTHER 1

Study Type

Interventional 6

Sponsor

Cancer Type

Tumor-Agnostic 2Gastrointestinal 2Thoracic 1Plasma cell 1Other solid neoplasm 1Genitourinary 1Breast 1

Conditions

Neoplasms 2Triple Negative Breast Neoplasms 1Solid Tumors 1Pancreatic Neoplasms 1Neoplasms, Plasma Cell 1Multiple Myeloma 1Hematologic Diseases 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma 1

Interventions

pembrolizumab 304Paclitaxel 206Carboplatin 200Gemcitabine 173Cisplatin 139Docetaxel 138Cyclophosphamide 136Nivolumab 129Bevacizumab 118Injections 111fludarabine 96atezolizumab 91Pemetrexed 90Dexamethasone 90Cetuximab 90Fluorouracil 84Irinotecan 77Rituximab 72Capecitabine 72venetoclax 71Azacitidine 70130-nm albumin-bound paclitaxel 67Leucovorin 65Fulvestrant 58Oxaliplatin 57durvalumab 56Trastuzumab 56Lenalidomide 55Ipilimumab 55Midazolam 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 1 × INDUSTRY × LCL161 × Clear all
NCT02890069 2023-01-11

A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat

Novartis

Phase 1 Completed
298 enrolled
BreastGastrointestinalGenitourinaryThoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT03111992 2022-02-09

Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma

Novartis

Phase 1 Completed
26 enrolled
Plasma cell

Hematologic Diseases, Multiple Myeloma, Neoplasms, Plasma Cell

NCT01240655 2020-12-19

A Study of LCL161 in Combination With Weekly Paclitaxel in Adult Patients With Advanced Solid Tumors

Novartis

Phase 1 Completed
76 enrolled
Other solid neoplasm

Solid Tumors

NCT01968915 2020-12-19

Safety and Tolerability of Oral LCL161 in Japanese Adult Patients With Advanced Solid Tumors

Novartis

Phase 1 Completed
9 enrolled
Tumor-Agnostic

Neoplasms

NCT01934634 2015-11-10

Phase I Trial of LCL161 and Gemcitabine Plus Nab-Paclitaxel in Metastatic Pancreatic Cancer

US Oncology Research

Phase 1 Unknown
24 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT01098838 2012-08-03

Safety and Efficacy of LCL161 in Patients With Solid Tumors

Novartis

Phase 1 Completed
71 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡